癃闭舒胶囊联合非那雄胺治疗良性前列腺增生观察

目的:研究非那雄胺联合癃闭舒胶囊治疗良性前列腺增生(BPH)的疗效。方法:将前列腺体积>30mL、国际前列腺症状评分(IPSS)>15分的良性前列腺增生69例随机分为两组,治疗组给予非那雄胺及癃闭舒胶囊联合治疗,对照组单独予非那雄胺治疗。治疗3月后,观察两组治疗前后最大尿流率、IPSS、超声测量残余尿。结果:两组患者IPSS评分、残余尿量和最大尿流率在治疗3月后与治疗前对比均有显著性差异(P<0.05),治疗组优于对照组,两组比较在治疗各时段IPSS、残余尿量和最大尿流率对比无显著性差异(P>0.05)。结论:对前列腺体积中度增大并合并下尿路症状(LUTS)的BPH患者,予非那雄胺和癃闭舒胶囊联合治疗,可获得满意疗效。     

膀胱内前列腺突出程度与良性前列腺增生临床评价指标的相关性

目的:探讨在良性前列腺增生(BPH)患者中,应用经腹超声测量的前列腺向膀胱内突出(IPP)程度与BPH常用临床评价指标的相关性。方法:对275例因下尿路症状就诊的BPH患者行经腹超声通过中线矢状面测量IPP,并且将IPP程度分别与患者年龄、前列腺体积、国际前列腺症状评分(IPSS)、最大尿流率和排尿后残余尿量进行相关分析。结果:275例BPH患者的IPP程度与年龄(r=0.210,P<0.01)、前列腺体积(r=0.534,P<0.01)和排尿后残余尿量(r=0.314,P<0.01)呈正相关关系,与最大尿流率(r=-0.364,P<0.01)呈负相关关系,而与IPSS(r=0.064,P=0.299)无明显相关。结论:IPP程度可能与症状性BPH患者的年龄和前列腺体积存在一定相关性。经腹超声测量IPP可能是一种评价BPH患者膀胱出口梗阻状态及程度的有价值的无创性方法。     

爱活尿通治疗良性前列腺增生的临床研究

目的:探讨爱活尿通(Eviprostat)治疗良性前列腺增生(BPH)的安全性及有效性。方法:采用开放、多中心的临床试验方法,对100例BPH患者进行了为期12周的观察。患者服用爱活尿通每次2片,每天3次,共12周。主要疗效指标为国际前列腺症状评分(IPSS),最大尿流率(Qm ax),膀胱残余尿量(Ru)和前列腺体积(V);次要指标为生活质量评分(QOL)和平均尿流率(Qave)。结果:服药12周后,IPSS评分较治疗前平均降低5.67分(P<0.001),QOL评分平均降低1.44分(P<0.001),Qm ax较治疗前平均增加1.70 m l/s(P<0.001),Qave平均增加1.15 m l/s(P<0.001),膀胱残余尿量(Ru)平均减少5.07 m l(P=0.046),PSA平均下降0.129μg/L(P<0.017)。临床不良反应发生率为1%。结论:爱活尿通可明显改善BPH患者的排尿症状、增加尿流率、减少残余尿量,不良反应发生率低,是一种安全、有效的治疗BPH的药物。     

福施乐治疗良性前列腺增生的临床研究

目的:观察福施乐治疗BPH的有效性和安全性。方法:采用多中心、开放性、自身前后对照的临床研究方法,对60例BPH患者采用福施乐治疗12周。以国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、膀胱残余尿(PVR)和前列腺体积为主要疗效指标,以生活质量评分(QOL)和平均尿流率(Qave)为次要疗效指标,来评价福施乐治疗BPH的效果。结果:治疗12周后,患者IPSS评分、Qmax、PVR、QOL评分、Qave均比治疗前明显改善(P<0.01),而前列腺体积治疗前后无显著性差异(P>0.05)。结论:福施乐可明显改善BPH患者的排尿症状,增加尿流率,减少残余尿,无明显不良反应,治疗BPH安全、有效。     

良性前列腺增生患者膀胱内前列腺突入测定的临床意义

目的探讨良性前列腺增生（BPH）患者前列腺突入膀胱内的程度对膀胱出口梗阻及逼尿肌功能的预测与评价。方法以经腹超声证实前列腺突入膀胱内的BPH患者为研究组,无突入的患者为对照组,分析两组间临床资料及尿动力学检查结果的关系。结果研究组临床资料中,前列腺体积、残余尿量、急性尿潴留及膀胱小梁化的比率与对照组相比差异有统计学意义（p〈0．05）,膀胱内前列腺突入程度与前列腺体积、残余尿量呈正相关（r分别为0．401,0．342,p值分别为0．013,0．0231）;在尿动力学结果中,研究组排尿期最大尿流率（Qmax）、逼尿肌不稳定及低顺应性膀胱的比率与对照组相比差异显著（p〈0．01）,排尿期最大逼尿肌压力（Pdet.max）及梗阻指数显著高于对照组（p〈0．05）,膀胱内前列腺突入程度与Qmax呈负相关（r=-0．284,p=0．045）,与Pdet．max及膀胱出口梗阻指数（BOOI）呈正相关（r分别为0．252,0．456,p值分别为0．041,0．032）。结论前列腺突入膀胱的BPH患者膀胱出口梗阻及膀胱功能受损的程度明显高于无突入患者;经B超测定膀胱内前列腺突入的程度,可以预测及评价膀胱出口梗阻的程度和膀胱功能的改变。     

坦索罗辛与非那雄胺联合治疗老年良性前列腺增生临床疗效观察

目的:观察盐酸坦索罗辛单药与非那雄胺联合治疗老年良性前列腺增生症(BPH)的疗效.方法:将101例BPH患者分为单药治疗组(对照组54例)和联合治疗组(治疗组47例),对照组予坦索罗辛胶囊0.2mg qd口服,治疗组予同时联合保列治5 mg qd口服,两组均连续用药3个月.观察治疗前后国际前列腺症状评分(IPSS)、最大尿流率(MFR)、经腹B超测膀胱残余尿量(PRV)、前列腺体积的变化.结果:与治疗前比较,治疗后两组患者的IPSS评分、MFR及PRV均明显改善(P＜0.05或＜0.01),前列腺体积的改变差异无统计学意义;两组治疗后比较,治疗组IPSS明显较低,而MFR明显较高,差异有统计学意义(P＜0.05).结论:坦索罗辛单药及与非那雄胺联合治疗均能改善BPH患者病情,但两药联合治疗疗效更好.     

前列腺光子治疗机治疗良性前列腺增生近期疗效观察(附30例报告)

目的 :观察Dolphin 2 0 0 0前列腺光子治疗机治疗良性前列腺增生 (BPH)的有效性和安全性。 　方法 :用Dolphin 2 0 0 0前列腺光子治疗机经直肠近距离照射 ,总剂量为 72 6～ 810cGy ,治疗 30例重度BPH患者 ,治疗 1个月后复查。疗效观察指标包括国际前列腺症状评分 ,生活质量指数 ,直肠指诊 ,经直肠B超确定前列腺大小重量 ,经腹B超测定膀胱残余尿液 ,前列腺特异性抗原 (PSA)测定 ,测定最大尿流率和平均尿流率。安全性指标包括血常规、尿常规、肝肾功能及其他不良反应等情况。　结果 :治疗 1个月后 ,显效 18例 ,好转 9例 ,较差 3例。治疗后国际前列腺症状评分、前列腺体积、最大尿流率、残余尿均发生明显的变化 (除最大尿流率P <0 .0 5外 ,其余均为P <0 .0 1)。　结论 :Dolphin 2 0 0 0前列腺光子治疗机治疗重度BPH安全有效 ,无创伤 ,方便经济 ,尤其适用于合并有心脑血管疾病及高危的BPH患者。     

萘哌地尔治疗良性前列腺增生的疗效观察

目的 :评价萘哌地尔 (Naftopidil)治疗良性前列腺增生 (BPH)的有效性和安全性。　方法 :80例诊断为BPH的病人 ,随机分为试验组 4 0例和对照组 4 0例。试验组给予萘哌地尔片 2 5mg ,每晚口服 ,共 4 2d ;对照组给予盐酸坦索罗辛胶囊 0 2mg ,每晚口服 ,共 4 2d。采用随机、双盲、双模拟、阳性药物平行对照法 ,以国际前列腺症状评分 (IPSS)、最大尿流率 (Qmax)作为主要疗效指标 ,以生活质量评分 (QOL)、残余尿量、前列腺体积作为次要疗效指标。　结果 :两组治疗前后IPSS、Qmax、QOL比较差异均有显著性 (P <0 .0 5 ) ,治疗后两组间比较差异无显著性 (P >0 .0 5 ) ;残余尿量两组治疗前后比较差异均无显著性 (P >0 .0 5 ) ,治疗 6周后两组间比较差异有显著性 (P <0 .0 5 ) ,前列腺体积治疗前后两组比较及两组间差异均无显著性 (P >0 .0 5 )。总的不良事件较少 (3 75 % ) ,两组间比较差异无显著性 (P >0 .0 5 )。　结论 :萘哌地尔是治疗BPH的有效和安全的药物     

特拉唑嗪联合前列舒通胶囊治疗前列腺增生的临床效果分析

目的研究良性前列腺增生运用特拉唑嗪联合前列舒通胶囊治疗的临床效果。方法将80例前列腺增生患者随机分为两组各40例,对照组患者单纯服用特拉唑嗪4 mg/次,1次/d,晚睡前服用进行治疗,观察组患者在此治疗基础上联合应用前列舒通胶囊进行治疗,3粒/次,3次/d,连续治疗3个月,对两组患者治疗前后的前列腺症状进行评分(IPSS)、最大尿流率(Qmax)、前列腺体积、残余尿量,同时记录不良事件的发生率。结果治疗后观察组患者的IPSS评分、前列腺体积变化比对照组显著,两组间差异有统计学意义(P0.05);两组患者的Qmax、残余尿量相比差异无统计学意义(P0.05)。结论前列腺增生运用特拉唑嗪联合前列舒通胶囊治疗的临床效果显著,有效改善前列腺增生的症状,缩小前列腺的体积,提高最大尿流速度,效果较好。     

索利那新联合坦索罗辛对良性前列腺增生合并膀胱过动症的疗效及神经阻滞机制研究

目的分析索利那新联合坦索罗辛对良性前列腺增生(BPH)合并膀胱过动症的疗效及神经阻滞机制。方法随机将郑州大学第二附属医院2017-07—2018-07间收治的80例BPH合并膀胱过动症的患者分为2组,各40例。对照组给予坦索罗辛治疗,观察组给予索利那新联合坦索罗辛治疗。观察2组患者的国际前列腺症状(IPSS)评分、膀胱过度活动症自我评价量表(OABSS)评分、排尿期症状(VSS)评分、后储尿期症状(USPSS)评分、最大尿流率(Qmax)、尿量(VV)、平均尿流率(Qave)、残余尿量及不良反应。结果治疗前,2组患者的IPSS、OABSS、VSS、USPSS、Qmax、VV、Qave及残余尿量指标差异均无统计学意义(P0.05)。治疗后,2组患者的上述指标均明显改善,但观察组的改善效果显著优于对照组,差异均有统计学意义(P0.05)。而且观察组不良反应率低于对照组,差异有统计学意义(P0.05)。结论索利那新联合坦索罗辛治疗BPH合并膀胱过动症,可明显改善患者症状,不良反应少,安全有效。     

良性前列腺增生症规范化治疗方案的多中心临床研究

目的 比较不同种类药物治疗良性前列腺增生（BPH）的疗效与差异,确定不同药物对不同患者的最佳适应证。方法 采用随机平行对照、多中心临床研究方法,对2002年9月至2003年12月906例BPH患者,随机进入选择性α-受体阻滞剂特拉唑嗪、多沙唑嗪、坦索罗辛与萘哌地尔;50α-还原酶抑制剂非那雄胺与爱普列特以及植物制剂舍尼通等7种治疗药物组。每3个月随访一次,国际前列腺症状评分（IPSS）与生活质量评分（QOL）,最大尿流率（Qmax）与平均尿流率（Qave）,前列腺总体积（TPV）与前列腺移行带体积以及残余尿量为观察指标进行疗效评价。根据不同指标基线水平将患者进行分层,比较各治疗组患者主观指标IPSS和客观指标Qmax的改善情况。结果 基线指标分析显示,全组主观指标IPSS评分和客观指标Qmax水平与TPV以及移行带体积呈明显相关性（P〈0．01）。至随访6个月时各类药物均使BPH患者的主观指标IPSS与QOL评分及客观指标Qmax与残余尿量有明显改善。各种药物对主客观指标的影响程度的组间比较显示,对IPSS的改善无显著差异;5α-还原酶抑制剂类药物爱普列特与非那雄胺可以使TPV和移行带体积均明显缩小（P〈0．05）。将患者以前列腺体积〈35．5cm^3和≥35．5cm^3分为两层,在非那雄胺治疗的患者中Qmax平均增加5．7ml／s和2．2ml／s（P〈0．01）,在舍尼通、萘哌地尔及多沙唑嗪治疗组,≥35．5cm^3者症状改善更为明显（P〈0．05）。以IPSS〈20分和≥20分进行分层,各种药物的疗效均在≥20分时更为明显（P〈0．01）。结论 各种药物均可明显改善BPH患者的主、客观症状,各种药物的疗效均对基线IPSS评分较高的患者疗效更为明显。5α-还原酶抑制剂能明显减小前列腺体积,对于前列腺体积≥35．5cm^2者有更为明显的主客观疗效。     

癃闭舒胶囊治疗BPH的疗效与安全性观察

目的：观察癃闭舒胶囊治疗BPH的疗效与安全性。方法：将440例患者随机分为试验组（320例）和对照组（120例）,分别给予癃闭舒胶囊和前列舒乐颗粒,治疗4周后,观察两组治疗前后最大尿流率、前列腺重量、I-PSS与QOL。结果：两组患者治疗后最大尿流率、前列腺重量、I-PSS与QOL较治疗前均有明显改善（P〈0．01）;治疗前后试验组与对照组差值分别为2．36±1．66、1．76±0．78,2．71±0．58、2．60±0．64,11．28±7．54、8．62±7．36,4．32±3．60、3．49±3．37。但治疗后两组比较,除前列腺重量外,其余均有统计学意义。结论：癃闭舒胶囊治疗BPH有明显的疗效且安全。     

Surgery (TUR-P) as a recommended initial treatment modality for the presented case

The pathophysiology of lower urinary tract dysfunction in the presented case comprised voiding dysfunction and overactive bladder. Two etiologies for voiding dysfunction in this case could be considered, bladder outlet obstruction due to benign prostatic hyperplasia (BPH) or detrusor underactivity. Prospected efficacies of pharmacological and surgical treatment (transurethral resection of prostate: TUR-P) for this case were compared based on a literature review. Alpha-1 blockers improve both voiding and storage symptoms in patients with BPH. However, improvement of maximum flow rate (Qmax) on uroflowmetry is limited within a small range and there is no evidence of significant reduction in residual urine volume. Alpha-1 blockers have no significant efficacy in improvement of objective measures in patients with detrusor underactivity. Although anticholinergics improve overactive bladder symptoms, they are contraindicated for patients with severe voiding dysfunction with residual urine. There is a lack of study on efficacy of apha-1 blocker administration combined with anticholinergics available in our hands for patients with BPH and overactive bladder. On the other hand, TUR-P brings remarkable improvement in voiding and storage symptoms, increase of flow rate and reduction of residual urine as a gold-standard surgical treatment for BPH. Urge incontinence and uninhibited detrusor contraction on cystometry reportedly disappeared in 60% of patients following TUR-P. TUR-P also improves subjective symptom and objective measures in patients with BPH and detrusor underactivity. Based on the literature review, surgery is recommended as a standard initial therapy for the presented patient with significant voiding dysfunction (Qmax 9.4 ml/sac and residual urine 72 ml).     

Home uroflowmetry: improved accuracy in outflow assessment

To study home uroflowmetry and to compare this method to free or "traditional" uroflowmetry in the evaluation of the patient with symptomatic benign prostatic hyperplasia (BPH), and the relationship between the values of home uroflowmetry parameters and bladder outlet obstruction (BOO). Twenty-five patients (mean age, 67 years) with symptomatic BPH were examined with home uroflowmetry, free uroflowmetry, and pressure-flow measurement. The patients were assessed using the International Prostate Symptom score; digital rectal examination; routine blood chemistry, including serum prostate-specific antigen level; urinanalysis; transrectal ultrasonography; and post-void residual urine. The 24 hr were divided into "active time" (AT) and "sleep time" (ST). AT home uroflowmetry parameters were compared to ST ones. The home uroflowmetry parameters were compared to respective ones of the free uroflowmetry as well and those obtained by pressure-flow measurement. The patients were asked about their opinion of home uroflowmetry. Home uroflowmetry was found to be a simpler and more acceptable method than free uroflowmetry. The mean Qmax of AT was significantly greater than the mean Qmax of ST, but the mean voided volume and mean voiding time of ST were significantly larger than those of AT. There was a close relationship between the mean Qmax at home and the Qmax in hospital, but the voided volume and voiding time measured in hospital were significantly larger than those at home. Home uroflowmetry provided an estimation of BOO for 46% of the patients as low if the home mean Qmax was >14 ml/sec, and as high if the home mean Qmax was <10 ml/sec. Home uroflowmetry was well accepted by the patients and gave more information than free uroflowmetry. In 46% of the cases, an estimation of BOO was obtained with home uroflowmetry.     

Comparative study of transurethral laser prostatectomy versus transurethral electroresection for benign prostatic hyperplasia

BACKGROUND: Transurethral resection of the prostate (TURP) is the gold standard treatment for benign prostatic hyperplasia (BPH). Recently, less invasive transurethral laser prostatectomy, such as visual laser ablation (VLAP) or interstitial laser coagulation (ILCP), have been developed. Herein, we investigated the efficacy of VLAP and ILCP compared to TURP. METHODS: A total of 80 patients with BPH were treated: 20 patients by VLAP, 30 patients by ILCP and 30 patients by TURP. All patients were followed up for 12 months after their operations. Treatment outcomes were evaluated by four different criteria: (i) the International Prostatic Symptom Score (I-PSS), (ii) the maximum flow rate (Qmax), (iii) postvoided residual urine volume before treatment and one, three, six and 12 months after treatment, and (iv) prostatic volume before operation and three and six months postoperatively. RESULTS: The I-PSS, Qmax and residual urine volume were significantly improved compared to baseline levels and the improvement continued for 12 months in the three groups: for I-PSS (P<0.001 in the VLAP group and P<0.0001 in the ILCP and TURP groups), Qmax (P<0.001 in the VLAP and ILCP groups, and P<0.0001 in the TURP group), residual urine volume (P<0.01 in the VLAP group and P<0.0001 in the ILCP and TURP groups). Significant reduction of the prostatic volume was recorded only in the ILCP and TURP groups (P<0.001). CONCLUSION: Visual laser ablation and ILCP can be good alternative treatments for BPH. Visual laser ablation provides good outcomes in patients with small-sized BPH and with risk factors such as heart disease or anticoagulation therapy.     

经尿道等离子双极电切治疗高龄高危前列腺增生症

目的总结经尿道等离子双极电切治疗高龄高危前列腺增生症患者的经验和观察其临床疗效。方法回顾分析我科于2015年1月~2017年6月采用经尿道等离子双极电切术,治疗60例高龄高危前列腺增生症的临床资料,记录术前患者的PSA、IPSS、QOL,统计手术时间、出血量、并发症发生率、术后住院时间等资料。结果本组60例患者均顺利完成,平均手术时间103±32.3 min,平均出血量62.6±34.4 mL,无输血,术后平均住院时间平均7.4±1.1 d。术后3月Qmax 19.8~26.3 mL/s,平均23.2±1.7 mL/s;IPSS 6~17分,平均11.6±2.5分;QOL 0~3分,平均1.26±0.78分,与术前相比差异有统计学意义,t值分别为31.1、29.5、36.6,所有P0.001。术后5例出现暂时性尿失禁,1例发生术后尿道狭窄,经对症处理情况改善后出院。平均随访15.68±7.32月,均未出现尿潴留,排尿畅。结论经尿道等离子双极电切治疗高龄高危前列腺增生症患者是安全的、有效的。     

Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short-term open, randomized multicenter study

BACKGROUND: The objective of this open randomized clinical study was to compare the short-term efficacy and safety of three alpha-1 blockers, prazosin, terazosin and tamsulosin, in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). METHODS: The study comprised 121 patients with symptomatic BPH who were randomized to receive 0.5 mg of prazosin twice daily, 0.5 mg of terazosin twice daily or 0.1 mg of tamsulosin once daily for the initial 2 weeks. The doses were doubled for the next 2 weeks. The primary variables assessed were a symptom score, changes in maximum and average urinary flow rate (Qmax and Qave), postvoid residual urine volume and blood pressure. RESULTS: The percentage changes in the total symptom score from baseline were 38, 39 and 26% at 4 weeks by prazosin, terazosin and tamsulosin, respectively. Terazosin produced significantly higher improvement in four out of nine individual symptoms than tamsulosin (P < 0.05). A significant increase in Qmax or Qave in uroflowmetry was obtained in the prazosin and tamsulosin groups. Blood pressure remained unchanged in normotensive patients, but significantly decreased in hypertensive patients except for the tamsulosin group. Adverse events were minimal in all treatment groups. CONCLUSIONS: The efficacy and safety profiles were different among the alpha-1 blockers at standard doses. Tamsulosin appears to be safer than the others for aged patients or patients with hypertension who have impaired blood pressure regulation, while terazosin is significantly effective in improving symptomatic score when compared with the others examined. It is recommended that the alpha-1 blocking agent and its optimal dose are selected on the basis of the baseline characteristics of the patients with symptomatic BPH.     

剩余分数在前列腺增生致膀胱出口梗阻中应用的评价

目的 :评价剩余分数 (RF) [剩余尿量 (PRV)除以排尿前尿量 (PV) ]在前列腺增生 (BPH)中判断膀胱出口梗阻程度的应用。　方法 :应用B型超声波检测仪及尿流参数自动检测仪对 5 0例患有BPH的门诊病人 (尿潴留及神经源性膀胱病人除外 )进行PV、PRV及最大尿流率 (Qmax)测定。分别用RF、PRV与Qmax作直线相关分析。结果 :RF与Qmax呈极显著负相关 (r =- 0 .385 9,P <0 .0 1) ,PRV与Qmax也呈显著负相关 (r =- 0 .2 831,P <0 .0 5 )。　结论 :RF值越大 ,膀胱出口梗阻愈严重 ,膀胱排尿功能愈差。RF这一评价BPH所致的膀胱出口梗阻程度的指标是对PRV的有益补充。     

经尿道等离子剜除术治疗巨大良性前列腺增生的疗效观察

目的 探讨经尿道等离子剜除术治疗巨大良性前列腺增生的疗效.方法 将2011年1月至2015年12月我科收治的65例巨大前列腺增生患者随机分为两组,分别应用经尿道前列腺等离子剜除术(33例)和经尿道等离子体前列腺电切术(32例)进行治疗,对比两组的相关临床指标.结果 与经尿道等离子体前列腺电切术组相比,经尿道前列腺等离子剜除术组的手术时间明显缩短(P<0.05),术中冲洗液量和术后血红蛋白水平下降值亦明显低于经尿道等离子体前列腺电切术组(P<0.05);术后复查,经尿道前列腺等离子剜除术组的最大尿流率明显高于经尿道等离子体前列腺电切术组(P<0.05),残余尿量明显低于经尿道等离子体前列腺电切术组(P<0.05).结论 对于巨大前列腺增生,与经尿道等离子体前列腺电切术比较,经尿道前列腺等离子剜除术的优势更明显,能更完全地切除腺体,缩短手术时间,降低术中出血量,值得临床推广应用.     

Prognostic value of a combination of IPSS,flow rate and residual urine volume compared to pressure-flow studies in the preoperative evaluation of symptomatic BPH

OBJECTIVE: Evaluate the predictive value of a combination of IPSS, uroflowmetry and ultrasound determination of residual urine volume in the determination of bladder outflow obstruction (BOO) and in predicting treatment outcome. METHODS: Forty-five out of a group of 60 BPH symptomatic patients were included. Preoperative evaluation: urine culture, PSA, uroflowmetry with sonographic measurement of post-void residual urine, DRE, IPSS with quality of life questions and pressure-flow study. Selection criteria for surgery were IPSS > 16 and Qmax < 10 ml/s. Transurethral resection of the prostate was performed in these patients; the control visit was performed at 3 months. Treatment success was defined as Qmax above 15 ml/s, residual urine of less than 100 ml, a 50% reduction in IPSS and absence of urinary retention. RESULTS: Urodynamic abnormalities were found in 42 patients (93.3%): 19 had detrusor instability, 5 patients showed impaired contractility, 37 patients had proven BOO, and 8 patients were unobstructed or mildly obstructed. The overall success rate was 86% when measured by the IPSS. Its preoperative value was 16.9, and dropped significantly to 4 (P = 0.005). The score improved significantly after surgery only in the obstructed group compared to the non-obstructed group (P = 0.001), however preoperative IPSS did not correlate with objective treatment results. CONCLUSIONS: A high proportion of patients successfully operated (71.1%) had a combination of IPSS > 16 and Qmax < 10 ml/s, although BOO could not be accurately predicted with non-invasive methods alone. Patients with no or mild infravesical obstruction had only minimal improvement of IPSS and uroflowmetry following surgery.